|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,090 DKK | -0.91% |
|
+4.11% | -18.05% |
| Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Orphazyme A/S reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was DKK 12.78 million compared to net income of DKK 62.98 million a year ago. Basic loss per share from continuing operations was DKK 360 compared to DKK 690 a year ago.
Basic loss per share was DKK 360 compared to basic earnings per share of DKK 1,790 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.05% | 5.51M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ORPHAZYME A/S 
